Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Dr Reddys Laboratories Ltd

    Dr. Reddys Laboratories Ltd was incorporated by its promoter and founder Chairman, Late Dr. K. Anji Reddy as a Private Limited Company on February 24, 1984. The company was su

  • No Image
    E W Nutrition India Pvt Ltd

    E W Nutrition India Pvt Ltd is a German based company engaged in research, development, manufacture, and marketing of food and feed products and additives for humans, livestock,